TARP and cancer: Antibodies are being developed to target other cancer-specific overexpressed intracellular proteins, such as human telomerase reverse transcriptase (hTERT), MUC1, NY-ESO1, TCR gamma alternate reading frame protein (TARP), p53, WT1, and preferentially expressed antigen of melanoma (PRAME) (94), with early clinical trial results for PRAME showing promising outcomes.